Compare BLLN & TRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLLN | TRMD |
|---|---|---|
| Founded | 2016 | 1889 |
| Country | United States | United Kingdom |
| Employees | 713 | N/A |
| Industry | Medical Specialities | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.9B |
| IPO Year | N/A | 2016 |
| Metric | BLLN | TRMD |
|---|---|---|
| Price | $80.12 | $26.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $129.57 | $34.00 |
| AVG Volume (30 Days) | 318.7K | ★ 1.0M |
| Earning Date | 03-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 8.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $45.89 | N/A |
| Revenue Next Year | $30.17 | N/A |
| P/E Ratio | ★ N/A | $9.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $61.96 | $13.63 |
| 52 Week High | $138.70 | $31.76 |
| Indicator | BLLN | TRMD |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 50.55 |
| Support Level | $63.98 | $21.54 |
| Resistance Level | $86.01 | $31.76 |
| Average True Range (ATR) | 5.61 | 0.89 |
| MACD | 1.30 | -0.35 |
| Stochastic Oscillator | 75.47 | 36.10 |
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
TORM plc operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.